Wegovy pill reaches UK patients and raises questions for doctors

A daily pill version of the weight-loss drug Wegovy is now reaching patients in the United Kingdom, weeks after regulators there authorized it, and doctors are already raising questions about how it should be prescribed and monitored ^[1]. The tablet, made by Novo Nordisk, is the same active ingredient, semaglutide, that is sold as an injection under the Wegovy name and used for diabetes under the Rybelsus name ^[1][2].

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved the semaglutide tablet on June 11, 2026, for adults with a body mass index (BMI) of 30 or above, or those with a BMI of 27 to 30 who also have at least one weight-related health condition, alongside a reduced-calorie diet and more physical activity ^[2]. As of early July, the pill became available for patients to buy privately at UK pharmacies and online chemists, according to The BMJ ^[1]. It is not yet available through Britain's National Health Service, because it still must be reviewed for cost-effectiveness by the National Institute for Health and Care Excellence (NICE) ^[1][2].

Dosing starts at 1.5 milligrams once daily and increases over time to 4 mg, 9 mg, and finally 25 mg, with at least one month spent at each dose level before moving up ^[2]. Patients already using the 2.4 mg weekly injectable version of semaglutide privately can switch directly to the 25 mg tablet ^[2]. The UK's health agency instructs patients to take the tablet whole, on an empty stomach after fasting at least eight hours, with a small sip of water, and to avoid food or drink for at least 30 minutes afterward, because eating or drinking too soon lowers how much of the drug the body absorbs ^[2]. The most common side effects reported are gastrointestinal problems, including nausea, diarrhea, constipation, and vomiting ^[2].

The BMJ reported that the rollout has prompted debate among UK doctors over prescribing, monitoring, and how to manage demand for the pill ^[1]. The article noted this is the first GLP-1 receptor agonist tablet authorized in the UK specifically for weight loss, distinct from the oral semaglutide tablet already sold there under the Rybelsus brand for type 2 diabetes ^[1].

Why it matters for patients

This development took place in the United Kingdom under UK regulators, not the U.S. Food and Drug Administration, so it does not change what is available at U.S. pharmacies. Still, it offers an early look at issues that could surface if a similar weight-loss tablet reaches the U.S. market: how prescribers decide who qualifies by BMI and health conditions, how patients manage strict dosing rules like fasting and timing food, and how insurers or national health systems weigh cost before covering a new pill form. In the UK, the tablet is available only through private purchase for now, since NICE has not yet finished its cost-effectiveness review ^[1][2]. Anyone using GLP-1 medications, in any form, deals with the same category of gastrointestinal side effects noted by UK regulators, including nausea, diarrhea, constipation, and vomiting ^[2].

What happens next

The sources do not say when NICE will complete its review or whether the pill will be added to NHS coverage. It is also not yet known from these sources whether or when a comparable semaglutide weight-loss tablet might be reviewed or approved by the FDA for the U.S. market. The MHRA said it will keep monitoring the drug's safety and effectiveness and encouraged reporting of side effects through its Yellow Card scheme ^[2].